Introduction

43
Enterococcus faecalis is a Gram-positive bacterium that normally colonizes the gastrointestinal mediated primarily by plasmids and integrative conjugative elements (5-7). One of the most derived from two independent conjugation experiments. The transconjugant colonies were each 121 resuspended in brain heart infusion (BHI) broth, and the percentage of erythromycin-resistant 122 cells and the size and Sanger sequence of the CRISPR3 amplicon was determined for each
123
( Fig S2; these data are discussed below). These data are referred to as "Day 0." Next, the 124 colony resuspensions were split equally into BHI medium and BHI medium with erythromycin.
125
These populations were then passaged daily over a period of 14 days. Every 24 h during the 126 course of the passage, the percentage of erythromycin-resistant cells relative to the total viable 127 population and the size and Sanger sequence of the CRISPR3 amplicon were determined.
after 1 day of passage in the presence of erythromycin and identified a mutation resulting in an
146
Ala749Thr substitution. Ala749 occurs within the RuvC nuclease domain in T11RF Cas9 and is 147 conserved in the model Streptococcus pyogenes Cas9 (32). Due to the critical catalytic function of the RuvC domain, we hypothesize that the Ala749Thr substitution confers a loss of Cas9 149 function. We tested the ability of the BHI-and erythromycin-passaged WT4 populations to 150 interfere with plasmid transfer using derivatives of the PRP, pCF10 (45) , that are targeted by
151
CRISPR3 spacers 1, 6, and 7. These experiments revealed that the Ala749 mutation indeed 152 renders these populations deficient for CRISPR-Cas activity (Fig 2) . 
156
the presence of erythromycin, we observed stable maintenance of erythromycin resistance in 157 both WT and Δcas9 transconjugants (Fig 1c) . We amplified the CRISPR3 region of 
163
populations revealed that S6 was either deleted from the array or had low sequencing quality 164 (Table 2 ). In contrast to WT populations, CRISPR3 arrays for the T11RFΔcas9(pAM714) 165 transconjugants were unchanged (Fig 1d and Table 2 ). We chose the Δ4 population as a 166 representative of the T11RFΔcas9(pAM714) transconjugant populations for future analyses.
168
To investigate the possibility of mutations within cas genes, we performed whole genome some of the populations possessed variation in one or more genes, none of which are predicted to have an impact on the phenotypes observed in our study (STable2) . No mutations were 175 identified in the S6 protospacer or PAM region of the repB gene in pAM714. However, we did 176 identify a mutation within repB, not associated with the protospacer or PAM, in the WT2 177 population (STable2). The sequencing also allowed us to investigate the possibility of Tn917 
185
we attained an average of 16 million reads for our amplicons (STable3). We first mapped
186
CRISPR3 amplicon reads to the T11 reference sequence and calculated coverage depth to 187 analyze mapping efficiency for BHI-passaged T11RF (lacking pAM714) (Fig. 3a) and the Δ4 188 transconjugant population passaged in erythromycin (Fig. 3b) as controls. We then expanded 189 this analysis to the T11RF(pAM714) transconjugants. As expected, depletion of S6 was detected 190 in WT2, WT3, WT5, and WT6 populations after 14 days of passage with antibiotic selection (Fig   191   3d-g ). For WT3, WT5, and WT6 populations, S6 depletion was evident after one day of passage 192 with selection (Fig 3e-g ). For WT1, depletion of S6 was not detected after 14 days passage with 193 selection (Fig 3c) , consistent with our Sanger sequencing results (Table 2) .
To identify specific mutant CRISPR3 alleles in the amplicon sequencing, we manually 
211
CRISPR3 references (Fig 4) . Of the five T11RF transconjugant populations analyzed, all other 212 than WT1 possessed at least one mutant CRISPR3 allele after 14 days of passage with 213 antibiotic selection, and each of those alleles lacked S6 (Table 2 ).
215
We tested the ability of the Day 14 WT5 population to prevent the acquisition of pCF10 and 216 pCF10 derivatives that are targeted by CRISPR3 spacers 1, 6 and 7. Based on deep 217 sequencing data (Table 2) , we expected that the WT5 population would interfere with transfer of 218 pCF10 bearing spacer 1, but not pCF10 bearing spacers 6 or 7. Compared to the BHI-passaged 219 WT5 population that significantly reduced the acquisition of each of the pCF10 derivatives, the 220 erythromycin-passaged WT5 population was unable to interfere with pCF10 bearing targets of spacer inversions, where a leader distal spacer becomes more leader proximal, have not been 226 extensively studied. Due to the high sequence depth achieved in our study, we were able to 227 observe both events and monitor their dynamics for the duration of the serial passaging 228 experiments. Among our 484 artificial references, the spacer deletion group is represented by 229 the mutant alleles where a spacer has been removed from its natural position (5'-SxRSy-3'
230
where y > x+1 and 5'-SxTRST-3' where x < 21), while the spacer inversion group is represented 231 by the mutant alleles where a terminal spacer has become more leader-proximal (5'-SxRSy-3' 232 where y < x). We calculated spacer deletion and spacer inversion rates for each spacer as 233 described in Materials and Methods.
235
In Day 1 and Day 14 BHI-passaged T11RF amplicons, we observed slightly higher spacer 236 deletion rates than spacer inversion rates for leader end spacers, suggesting that spacers at the 237 leader end are more readily deleted than inverted in naturally occurring CRISPR3 arrays (Fig   238   5a ). On average, Day 14 T11RF showed slightly lower rates for deletion and inversion events 239 than Day 1 T11RF. However, the deletion and inversion rates were similar at spacers S9-S15 for
240
Day 1 and Day 14 T11RF populations, indicating an equal chance of spacer deletion and 241 inversion (Fig 5a) . Terminal end spacers are associated with decreased deletion and inversion 242 rates compared to leader end spacers. Interestingly, the inversion rates of terminal end spacers 243 are slightly higher than the rates for leader end spacers. We hypothesize that the increased 244 spacer inversion rates for terminal spacers is due to a greater number of homologous
12
The deletion and inversion rates of five T11RF(pAM714) transconjugants and the Δ4 population 249 from Day 1 and Day 14 erythromycin passages were evaluated in the same manner as the 250 T11RF population. The distribution of deletion and inversion rates in the Δ4 and WT1 251 populations (Fig 5b and c) were similar to T11RF (Fig 5a) 
259
spacer inversion rates in erythromycin-passaged transconjugants (Fig 5 d-g ), indicating that 260 spacers are more readily deleted than rearranged.
262
Spacer deletion is not exclusively RecA-dependent. Under antibiotic selection,
263
T11RF(pAM714) transconjugants lost S6 to resolve the conflict between CRISPR-Cas and its 264 target. The loss of S6 was often coupled with the loss of surrounding spacers, ranging from S1 to 265 S18 (Table 2) . From our amplicon sequencing data, we noticed that the rearrangements 266 associated with shortened CRISPR3 arrays occurred between repeat-spacer junctions leaving 267 behind perfectly intact repeat-spacer-repeat sequences that are still functional for CRISPR 268 interference (Fig 2) . This observation led us to hypothesize that either homologous 269 recombination or slippage during DNA replication plays a role in eliminating spacers from the 270 array, as has also been hypothesized by other groups (33, 34, 37, 38) .
272
To study if homologous recombination had an impact on spacer loss, we constructed an in-273 frame deletion of recA in T11RF, generating strain T11RFΔrecA, and used it as a recipient in type CRISPR3 array in the recA mutant with Sanger sequencing. Across three independent 276 trials, only 12 transconjugant colonies were obtained. We selected two transconjugants
277
(recA.TC1 and recA.TC2) for 14 day serial passaging with continuous erythromycin selection.
278
PCR analysis for CRISPR3 amplicons of Day 0 recA.TC1 and recA.TC2 transconjugant 279 colonies and the amplicons after 1 and 14 days of passage in erythromycin are shown in Figure   280 6. We used Sanger sequencing to assess spacer loss events in Day 1 and Day 14 populations,
281
but not Day 0 transconjugants. We determined that recA.TC1 had lost S6 after 1 day of passage 282 in erythromycin, while the recA.TC2 population had a deletion of S6-S7. The same CRISPR3 283 alleles detected by Sanger sequencing after 1 day of passage were also observed at Day 14. 
287
Cas system that is distinct in sequence and function from the CRISPR3-Cas system of E.
288
faecalis T11RF (22, 32). The CRISPR1-Cas system possesses identical repeats and is 289 functionally linked to the orphan CRISPR2 locus, which occurs in all E. faecalis (22, 32, 39, 46) .
290
We wanted to determine if introducing a plasmid targeted by either CRISPR1-Cas or CRISPR2
291
would impact the integrity of the other locus within the same cell under continuous antibiotic 292 selection for the plasmid target.
294
For these studies, we used the well-characterized human oral isolate OG1RF in combination 295 with pKH12-derived plasmids (Table 1) that were described by Hullahalli et al (39) . pKH12 is a 296 chloramphenicol resistant shuttle vector that is mobilizable by the oriT sequence derived from were each transformed into electrocompetent OG1RF. The initial integrity of the CRISPR1-Cas 304 and CRISPR2 arrays, regardless of the plasmid transformed, was confirmed to be wild-type by
305
Sanger sequencing.
307
Three transformants for each plasmid were selected to be used in serial passaging 
330
We previously demonstrated that the CRISPR3-Cas system of the natively drug sensitive E.
331
faecalis isolate T11RF significantly reduced acquisition of the PRP pAM714 in a cas9-and 332 spacer 6-dependent mechanism (32). The plasmid pAM714 is a derivative of the model PRP 
340
In our previous study, we observed a substantial number of T11RF(pAM714) transconjugants, 341 despite CRISPR3-Cas activity. Based on previous data in other organisms (33, 34, 38), we 342 hypothesized that conjugation occurred into T11RF recipient cells with pre-existing CRISPR-343 inactivating mutations. However, recent data from our lab on another CRISPR-Cas system in E.
344
faecalis and using different model strains indicated that this hypothesis was incomplete.
345
Specifically, we observed spacer deletion mutants emerging over time in E. faecalis populations 346 having CRISPR-Cas and a plasmid target in intracellular conflict (39) (39) and are depleted from the population over time, or, a slow-acting CRISPR-Cas 359 system progressively scrubs the plasmid from the population over time.
361
We used erythromycin resistance as a marker for pAM714 carriage. We acknowledge that the 362 erythromycin marker is encoded within Tn917, which could theoretically integrate into the 
370
The plasmid pAM714 encodes a toxin-antitoxin system (44, 48, 49) . The system encodes a 371 stable toxin that will kill daughter cells that have not inherited a plasmid copy; an unstable 372 antitoxin is encoded from the same locus that blocks toxin translation in cells with proper 373 plasmid segregation. However, in our study, we observed a gradual decrease of erythromycin-374 resistant cells when we passaged T11RF(pAM714) in BHI for 14 days, indicating that the toxin-repeats and spacers that make up the CRISPR3 array. We determined that natural 379 heterogeneity in CRISPR3 exists at a low frequency in wild-type T11RF populations. We reason 380 that heterogeneity could result from slippage during DNA replication and/or recombination 381 between CRISPR3 direct repeat sequences, consistent with previous research that proposed 382 that heterogeneity exists within CRISPR arrays in bacterial populations (33, 34, 38) .
383
Furthermore, our results demonstrate that spacer deletion can occur in the absence of recA, 384 which implicates DNA replication slippage in the emergence of mutant CRISPR alleles.
385
However, the fact that we observed the occurrence of spacer inversions indicates that 386 homologous recombination does play a role in the inherent allelic diversity of CRISPR arrays. It 387 is likely that both recombination and replication slippage contribute to the emergence of 388 heterogeneous CRISPR alleles. We do not have an estimate of which process has a greater 389 effect, nor whether additional stresses beyond antibiotic selection could influence rates for each.
391
There were consequences to the resolution of CRISPR/plasmid conflicts in E. faecalis populations.
392
In one case, in which pAM714 conjugated into a recipient with a pre-existing cas9 mutation (WT4), 393 the population could no longer impede entry of PRPs bearing CRISPR targets. For another 394 population, WT5, its susceptibility to future plasmid transfer events was dependent upon whether it 395 was passaged with erythromycin. The WT5 population passaged without erythromycin could 396 impede entry of PRPs bearing CRISPR targets at levels comparable to the wild-type control.
397
However, the WT5 population passaged with erythromycin, in which multiple CRISPR deletion 398 alleles arose, lost the ability to defend against PRPs bearing certain spacer targets. In effect,
399
antibiotic selection for pAM714 selected for the emergence of mutants with compromised CRISPR-
400
Cas. We also observed that the acquisition frequencies of pCF10 and its derivatives were higher for 401 all populations possessing pAM714 (WT5-Erm, WT4-BHI, and WT4-Erm). We infer that pAM714 402 enhances pCF10 conjugation frequency via an unknown mechanism. This was an unanticipated additional outcome of the enforced maintenance of pAM714, and it remains to be determined 
414
Materials and Methods
416
Strains, reagents, and routine molecular biology procedures. Bacterial strains and plasmids 417 used in this study are listed in Table 1 . E. faecalis strains were grown in Brain Heart Infusion 418 (BHI) broth or on agar plates at 37°C unless otherwise noted. Antibiotics were used for E.
419
faecalis at the following concentrations: erythromycin, 50 μg/mL; chloramphenicol, 15 μg/mL; 420 streptomycin, 500 μg/mL; spectinomycin, 500 μg/mL; rifampicin, 50 μg/mL; fusidic acid, 25 421 μg/mL. Escherichia coli strains used for plasmid propagation and were grown in lysogeny broth 422 (LB) broth or on agar plates at 37°C. Chloramphenicol was used at 15 μg/mL for E. coli. PCR 
450
(CFU/mL) was determined using plates with 30 -300 colonies. The conjugation frequency was selective BHI broth for plasmid selection, and another 10 μL was used for serial dilution and 
469
Deep sequencing of CRISPR3 amplicons and genomic DNA. For CRISPR3 amplicon 470 sequencing, 3 μL from a broth culture was used as template in PCR using Phusion Polymerase 471 with CR3_seq_F/R primers (STable1). The PCR products were purified using the Thermo
472
Scientific PCR purification kit (Thermo Scientific). Genomic DNA was isolated using the phenol- 
484
Detector. At the same time, local realignment was performed, followed by Fixed Ploidy variant 485 detection using default parameters and variants probability ≥90% in CLC Genomics Workbench.
486
The basic variants and fixed ploidy variants were combined for each sequencing sample and 487 subjected to manual inspection. The variants that were detected in the T11 genome from all 488 samples were inferred to be variants in our parent T11 stock and were manually removed. The 489 variants that were detected in pAD1 genome from all transconjugant samples were inferred to 490 be variants in our pAM714 stock, hence were also manually removed. Next, variants within the 491 CRISPR3 array were removed as we analyzed CRISPR3 alleles using a different approach 
516
were generated for the CRISPR3 amplicon. Considering that the read length is 150 bp, we 517 manually split each read into two subsequences (one subsequence was 75 bp; with the 518 remainder of the read being the second subsequence) to enhance mapping efficiency, allowing 519 for retrieval of maximal sequence information. The split amplicon sequencing reads were 520 mapped to the 5'-SxRSy-3' and 5'-SxTRST-3' references using stringent mapping parameters in 521 CLC Genomics Workbench (Qiagen). The stringent mapping parameters require 100% of each 522 mapped read to be ≥95% identical to one unique reference. Thus, the sequencing reads from 523 different CRISPR alleles will be distinguished. These amplicon mapping results were applied to 524 the calculation of forward spacer deletion and backward spacer rearrangement rates.
526
To further evaluate the mapping efficiency, the unmapped reads from initial mapping to the T11 527 CRISPR3 reference (STable3, step 1) were subjected to additional quality control analysis. The 528 unmapped reads were mapped to the 484 manually created spacer[x]-repeat-spacer [y] parameters, ignoring unspecific mapping (80% of each mapped read has at least 50% identity 533 to the reference sequence; STable3, step 3 mapping). The unmapped reads from step 3 were 534 mapped to all possible references using the default mapping parameters and randomly map 535 unspecific matching reads (STable3, step 4 mapping).
537
Forward spacer deletion and backward spacer rearrangement. We observed two categories 
548
where n is the total number of spacers within a CRISPR array, hence Sn represents terminal 549 spacer, as described above (Fig S1a) .
551
Accession number.
552
The sequencing data for amplicon and whole genome sequencing analysis of transconjugant 
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The beginning and end of the regions along the amplicon corresponding to S1, S6 and S21 within 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 Table S1 . Primers used in this study. Table S2 . SNPs detection in all gDNA sequencing samples. Table S3 . Quality control of the amplicon sequencing reads.
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